Compare Royal Caribbean Cruises Ltd (RCL) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs Travere Therapeutics Inc. Common Stock — how do they compare? Royal Caribbean Cruises Ltd trades at $276.94 (market cap $73.36B), while Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 14.6× Travere Therapeutics Inc. Common Stock's market cap, and Royal Caribbean Cruises Ltd pays a 2.19% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royal Caribbean Cruises Ltd for 85 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| RCL | TVTX | |
|---|---|---|
Market Cap | $73.36B | $5.02B |
Volume | 1,222,673 | 2,060,842 |
Sector | Consumer Cyclical | Health |
52-Week High | $348.03 | $67.52 |
52-Week Low | $230.30 | $26.79 |
Typical Hold Time | 85 Days | 0 Days |
Enterprise Value | $96.01B | $5.15B |
Dividend Yield | 2.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $281.51, up 0.3% with a bullish technical signal and strong fundamental momentum. The company has delivered consecutive earnings beats in Q1 and Q2 2026, with revenue growing from $8.8B in 2022 to $17.9B in 2025. Analyst consensus is bullish with a $344.17 price target, supported by positive cash flow trends and expanding profit margins. Recent developments include a $3B investment in Sandals Resorts, creating new growth avenues beyond traditional cruise operations.
RCL presents a compelling investment case with strong earnings momentum, improving debt metrics, and strategic expansion into resorts. However, risks include execution challenges from the Sandals acquisition, fuel cost volatility with $1.34B projected for 2026, and competitive pressures in the cruise industry. The stock's current valuation at 16.94 P/E appears reasonable given 45.33% ROE and consistent margin expansion.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
